The peer-reviewed JAMA Network published a study today that found in a randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease.
This study’s findings, published on February 18, 2022, do not support the use of low-dose ivermectin for COVID-19 patients at risk.
These 500 randomized COVID-19 patients received Ivermectin 0.4mg/kg of body weight/day for 5 days.
Read More
